Literature DB >> 18420034

Detection of lung cancer using weighted digital analysis of breath biomarkers.

Michael Phillips1, Nasser Altorki, John H M Austin, Robert B Cameron, Renee N Cataneo, Robert Kloss, Roger A Maxfield, Muhammad I Munawar, Harvey I Pass, Asif Rashid, William N Rom, Peter Schmitt, James Wai.   

Abstract

BACKGROUND: A combination of biomarkers in a multivariate model may predict disease with greater accuracy than a single biomarker employed alone. We developed a non-linear method of multivariate analysis, weighted digital analysis (WDA), and evaluated its ability to predict lung cancer employing volatile biomarkers in the breath.
METHODS: WDA generates a discriminant function to predict membership in disease vs no disease groups by determining weight, a cutoff value, and a sign for each predictor variable employed in the model. The weight of each predictor variable was the area under the curve (AUC) of the receiver operating characteristic (ROC) curve minus a fixed offset of 0.55, where the AUC was obtained by employing that predictor variable alone, as the sole marker of disease. The sign (+/-) was used to invert the predictor variable if a lower value indicated a higher probability of disease. When employed to predict the presence of a disease in a particular patient, the discriminant function was determined as the sum of the weights of all predictor variables that exceeded their cutoff values. The algorithm that generates the discriminant function is deterministic because parameters are calculated from each individual predictor variable without any optimization or adjustment. We employed WDA to re-evaluate data from a recent study of breath biomarkers of lung cancer, comprising the volatile organic compounds (VOCs) in the alveolar breath of 193 subjects with primary lung cancer and 211 controls with a negative chest CT.
RESULTS: The WDA discriminant function accurately identified patients with lung cancer in a model employing 30 breath VOCs (ROC curve AUC=0.90; sensitivity=84.5%, specificity=81.0%). These results were superior to multilinear regression analysis of the same data set (AUC=0.74, sensitivity=68.4, specificity=73.5%). WDA test accuracy did not vary appreciably with TNM (tumor, node, metastasis) stage of disease, and results were not affected by tobacco smoking (ROC curve AUC=0.92 in current smokers, 0.90 in former smokers). WDA was a robust predictor of lung cancer: random removal of 1/3 of the VOCs did not reduce the AUC of the ROC curve by >10% (99.7% CI).
CONCLUSIONS: A test employing WDA of breath VOCs predicted lung cancer with accuracy similar to chest computed tomography. The algorithm identified dependencies that were not apparent with traditional linear methods. WDA appears to provide a useful new technique for non-linear multivariate analysis of data.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18420034      PMCID: PMC2497457          DOI: 10.1016/j.cca.2008.02.021

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  27 in total

1.  Demonstration that menthofuran synthase of mint (Mentha) is a cytochrome P450 monooxygenase: cloning, functional expression, and characterization of the responsible gene.

Authors:  C M Bertea; M Schalk; F Karp; M Maffei; R Croteau
Journal:  Arch Biochem Biophys       Date:  2001-06-15       Impact factor: 4.013

2.  Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer.

Authors:  A Hoos; H H Hepp; S Kaul; T Ahlert; G Bastert; D Wallwiener
Journal:  Int J Cancer       Date:  1998-02-20       Impact factor: 7.396

3.  Metabolic interaction of n-hexane and methyl ethyl ketone in vitro in a head space rat liver S9 vial equilibration system.

Authors:  B Mortensen; K Zahlsen; O G Nilsen
Journal:  Pharmacol Toxicol       Date:  1998-02

4.  Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy.

Authors:  J Sharkey; S D Chovnick; R J Behar; R Perez; J Otheguy; R Rabinowitz; J Steele; C Webster; M Donohue; Z Solc; W Huff; A Cantor
Journal:  J Endourol       Date:  2000-05       Impact factor: 2.942

5.  Genotoxic activation of benzophenone and its two metabolites by human cytochrome P450s in SOS/umu assay.

Authors:  Kei Takemoto; Hiroshi Yamazaki; Miki Nakajima; Tsuyoshi Yokoi
Journal:  Mutat Res       Date:  2002-08-26       Impact factor: 2.433

Review 6.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

7.  Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.

Authors:  David K Ornstein; Walter Rayford; Vincent A Fusaro; Thomas P Conrads; Sally J Ross; Ben A Hitt; Wesley W Wiggins; Timothy D Veenstra; Lance A Liotta; Emanuel F Petricoin
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

8.  Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study).

Authors:  Michael Phillips; John P Boehmer; Renee N Cataneo; Taseer Cheema; Howard J Eisen; John T Fallon; Peter E Fisher; Alan Gass; Joel Greenberg; Jon Kobashigawa; Donna Mancini; Barry Rayburn; Mark J Zucker
Journal:  J Heart Lung Transplant       Date:  2004-06       Impact factor: 10.247

9.  Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.

Authors:  Joachim Schneider; Gregor Peltri; Norman Bitterlich; Kathleen Neu; Hans-Georg Velcovsky; Harald Morr; Norbert Katz; Erich Eigenbrodt
Journal:  Anticancer Res       Date:  2003 Mar-Apr       Impact factor: 2.480

View more
  44 in total

1.  Application of femtosecond laser mass spectrometry to the analysis of volatile organic compounds.

Authors:  Min Liu; Chengyin Wu; Zhifeng Wu; Hong Yang; Qihuang Gong; Wei Huang; Tong Zhu
Journal:  J Am Soc Mass Spectrom       Date:  2010-02-18       Impact factor: 3.109

2.  A gate-opening controlled metal-organic framework for selective solid-phase microextraction of aldehydes from exhaled breath of lung cancer patients.

Authors:  Li-Qing Yu; Li-Ya Wang; Fei-Hong Su; Ping-Yu Hao; Huan Wang; Yun-Kai Lv
Journal:  Mikrochim Acta       Date:  2018-05-22       Impact factor: 5.833

3.  Stability of selected volatile breath constituents in Tedlar, Kynar and Flexfilm sampling bags.

Authors:  Paweł Mochalski; Julian King; Karl Unterkofler; Anton Amann
Journal:  Analyst       Date:  2013-03-07       Impact factor: 4.616

4.  Noninvasive detection of lung cancer by analysis of exhaled breath.

Authors:  Amel Bajtarevic; Clemens Ager; Martin Pienz; Martin Klieber; Konrad Schwarz; Magdalena Ligor; Tomasz Ligor; Wojciech Filipiak; Hubert Denz; Michael Fiegl; Wolfgang Hilbe; Wolfgang Weiss; Peter Lukas; Herbert Jamnig; Martin Hackl; Alfred Haidenberger; Bogusław Buszewski; Wolfram Miekisch; Jochen Schubert; Anton Amann
Journal:  BMC Cancer       Date:  2009-09-29       Impact factor: 4.430

5.  Clinical applications of breath testing.

Authors:  Kelly M Paschke; Alquam Mashir; Raed A Dweik
Journal:  F1000 Med Rep       Date:  2010-07-22

Review 6.  Exhaled breath analysis for lung cancer.

Authors:  Annette G Dent; Tom G Sutedja; Paul V Zimmerman
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

7.  XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center.

Authors:  Franco M Muggia; Godefridus J Peters; Joseph R Landolph
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

8.  Accuracy and Methodologic Challenges of Volatile Organic Compound-Based Exhaled Breath Tests for Cancer Diagnosis: A Systematic Review and Meta-analysis.

Authors:  George B Hanna; Piers R Boshier; Sheraz R Markar; Andrea Romano
Journal:  JAMA Oncol       Date:  2019-01-10       Impact factor: 31.777

9.  Assessment of the exhalation kinetics of volatile cancer biomarkers based on their physicochemical properties.

Authors:  Anton Amann; Pawel Mochalski; Vera Ruzsanyi; Yoav Y Broza; Hossam Haick
Journal:  J Breath Res       Date:  2014-02-24       Impact factor: 3.262

10.  Prediction of blood:air and fat:air partition coefficients of volatile organic compounds for the interpretation of data in breath gas analysis.

Authors:  Christian Kramer; Paweł Mochalski; Karl Unterkofler; Agapios Agapiou; Veronika Ruzsanyi; Klaus R Liedl
Journal:  J Breath Res       Date:  2016-01-27       Impact factor: 3.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.